**Core Concept**
Diabetic Macular Edema (DME) is a complication of diabetes characterized by accumulation of fluid in the macula, leading to vision impairment. Treatment options for DME include anti-vascular endothelial growth factor (anti-VEGF) agents, corticosteroids, and laser photocoagulation.

**Why the Correct Answer is Right**
Anti-VEGF agents, such as ranibizumab and aflibercept, work by inhibiting the VEGF pathway, thereby reducing angiogenesis and fluid accumulation in the macula. Corticosteroids, like triamcinolone, decrease inflammation and edema. Laser photocoagulation destroys retinal tissue, reducing edema. On the other hand, **Option B: Sodium Phosphate** is used in the treatment of hyperphosphatemia, not DME. It works by promoting phosphate excretion in the urine, but it does not have a direct effect on the pathophysiology of DME.

**Why Each Wrong Option is Incorrect**
**Option A:** Not provided, but if it was a treatment option, it would be incorrect.
**Option C:** Not provided, but if it was a treatment option, it would be incorrect.

**Clinical Pearl / High-Yield Fact**
When treating DME, it's essential to consider the potential side effects of anti-VEGF agents, such as increased risk of endophthalmitis, retinal detachment, and cataract formation.

**Correct Answer:** B. Sodium Phosphate.